Clinically relevant drug interactions between newer antidepressants and oral anticoagulants

References

• Prince MJ, Wu F, Guo Y, et al. The burden of disease in older people and implications for health policy and practice. Lancet. 2015;385:549–562.
   Google Scholar
• Scheife RT, Hines LE, Boyce RD, et al. Consensus recommendations for systematic evaluation of drug–drug interaction evidence for clinical decision support. Drug Saf. 2015;38:197–206.
   Google Scholar
• Patel D, Mc Conkey ND, Sohaney R, et al. A systematic review of depression and anxiety in patients with atrial fibrillation: the mind-heart link. Cardiovasc Psychiatry Neurol. 2013;2013:159850.
   Google Scholar
• Stahl SM. Antidepressants. In: Stahl SM, editor. Stahl’s essential psychopharmacology. 4th ed. New York: Cambridge University Press; 2013. p. 284–369.
   Google Scholar
• Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: american college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(Suppl. 2):e44S–88S.
   Google Scholar
• Chan NC, Paikin JS, Hirsh J, et al. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions. Thromb Haemost. 2014;111:798–807.
   Google Scholar
• Scaglione F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists. Clin Pharmacokinet. 2013;52:69–82.
   Google Scholar
• Mekaj YH, Mekaj AY, Duci SB, et al. New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag. 2015;11:967–977.
   Google Scholar
• Nemeroff CB, Preskorn S, Devane CL. Antidepressant drug-drug interactions: clinical relevance and risk management. CNS Spectr. 2007;12(suppl 7):1–13.
   Google Scholar
• Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. Clin Ther. 2008;30:1206–1227.
   Google Scholar
• Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology. 2010;86:203–215.
   Google Scholar
• Spina E, Trifirò G, Caraci F. Clinically significant drug interactions with newer antidepressants. CNS Drugs. 2012;26:39–67.
   Google Scholar
• Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31:326–343.
   Google Scholar
• Hellwig T, Gulseth M. Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants. Ann Pharmacother. 2013;47:1478–1487.
   Google Scholar
• Fitzgerald JL, Howes LG. Drug interactions of direct-acting oral anticoagulants. Drug Saf. 2016;39:841–845.
   Google Scholar
• Voukalis C, Lip GYH, Shantsila E. Drug-drug interactions of non-vitamin K oral anticoagulants. Exp Opin Drug Metab Toxicol. 2016;12:1445–1461.
   Google Scholar
• Stollberger C. Drug interactions with new oral anticoagulants in elderly patients. Exp Rev Clin Pharmacol Ther. 2017;10:1191–1202.
   Google Scholar
• Di Minno A, Frigerio B, Spadarella G, et al. Old and new oral anticoagulants: food, herbal medicines and drug interactions. Blood Rev. 2017;31:193–203.
   Google Scholar
• Gelosa P, Castiglioni L, Tenconi M, et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res. 2018;135:60–79.
   Google Scholar
• Duncan D, Sayal K, MCConnell H, et al. Antidepressant interactions with warfarin. Int Clin Psychopharmacol. 1998;13:87–94.
   Google Scholar
• Sayal KS, Duncan-McConnell DA, MCConnell HW, et al. Psychotropic interactions with warfarin. Acta Psychiatr Scand. 2000;102:250–252.
   Google Scholar
• Nadkarni A, Oldham MA, Howard M, et al. Drug-drug interactions between warfarin and psychotropics: updated review of the literature. Pharmacotherapy. 2012;32:932–942.
   Google Scholar
• Teles JS, Fukuda EY, Feder D. Warfarin: pharmacological profile and drug interactions with antidepressants. Einstein. 2012;10:110–115.
   Google Scholar
• Spina E, Italiano D. Drug interactions. In: Shorvon S, Perucca E, Engel J, editors. Treatment of epilepsy. 4th ed. Oxford: Wiley-Blackwell Publishing Ltd.; 2015. p. 344–359.
   Google Scholar
• Spina E, Pisani F, de Leon J. Clinically significant pharmacokinetic drug interactions of antiepileptics with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86.
   Google Scholar
• Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 2002;71:115–121.
   Google Scholar
• Lin JH. Transporter-mediated drug interactions. Clinical implications and in vitro assessment. Exp Opin Drug Metab Toxicol. 2007;3:81–92.
   Google Scholar
• Gessner A, Konig J, Fromm MF. Clinical aspects of transporter-mediated drug-drug interactions. Clin Pharmacol Ther. 2019;105:1386–1394.
   Google Scholar
• El Ela AA, Hartter S, Schmitt U, et al. Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds–implications for pharmacokinetics of selected substrates. J Pharm Pharmacol. 2004;56:967–975.
   Google Scholar
• Feng B, Mills JB, Davidson RE, et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos. 2008;36:268–275.
   Google Scholar
• O’Brien FE, Dinan TG, Griffin BT, et al. Interactions between antidepressants and P-glycoprotein at the blood-brain barrier: clinical significance of in vitro and in vivo findings. Br J Pharmacol. 2012;165:289–312.
   Google Scholar
• Ruike Z, Junhua C, Wenxing P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol. 2010;25:553–559.
   Google Scholar
• Akamine Y, Yasui-Furukori N, Ieiri I, et al. Psychotropic drug-drug interactions involving P-glycoprotein. CNS Drugs. 2012;26:959–973.
   Google Scholar
• Weiss J, Dormann SM, Martin-Facklam M, et al. Inhibition of P-glycoprotein by newer antidepressants. J Phamacol Exp Ther. 2003;305:197–204.
   Google Scholar
• Saruwatari J, Yasui-Furukori N, Niioka T, et al. Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol. 2012;32:195–199.
   Google Scholar
• Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs. 2006;20:143–151.
   Google Scholar
• de Abajo FJ, Montero D, Rodriguez LA, et al. Antidepressants and risk of upper gastrointestinal bleeding. Basic Clin Pharmacol Toxicol. 2006;98:304–310.
   Google Scholar
• Anglin R, Yuan Y, Moayyedi P, et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:811–819.
   Google Scholar
• Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2015;13:42–50.
   Google Scholar
• Laporte S, Chapelle C, Caillet P, et al. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32.
   Google Scholar
• Bak S, Tsiropoulos I, Kjaersgaard JO, et al. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke. 2002;33:1465–1473.
   Google Scholar
• Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. Br J Clin Pharmacol. 2011;71:116–120.
   Google Scholar
• Lopponen P, Tetri S, Juvela S, et al. Association between warfarin combined with serotonin-modulating antidepressants and increased case fatality in primary intracerebral hemorrhage: a population-based study. J Neurosurg. 2014;120:1358–1363.
   Google Scholar
• Renoux C, Vahey S, Dell’Aniello S, et al. Association of selective serotonin reuptake inhibitors with the risk for spontaneous intracranial hemorrhage. JAMA Neurol. 2017;74:173–180.
   Google Scholar
• Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. CNS Drugs. 2018;32:321–334.
   Google Scholar
• Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–128.
   Google Scholar
• Andrade C, Sandarsh S, Chethan KB, et al. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry. 2010;71:1565–1575.
   Google Scholar
• de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28:345–367.
   Google Scholar
• Hallback I, Hagg S, Eriksson AC, et al. In vitro effects of serotonin and noradrenaline reuptake inhibitors on human platelet adhesion and coagulation. Pharmacol Rep. 2012;64:979–983.
   Google Scholar
• Van Walraven C, Mamdani MM, Wells PS, et al. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. Br Med J. 2001;323:2354–2358.
   Google Scholar
• Meijer WE, Heerdink ER, Nolen WA, et al. Association of risk of abnormal bleeding with degree of serotonin reuptake inhibition by antidepressants. Arch Intern Med. 2004;164:2367–2370.
   Google Scholar
• Vidal X, Ibanez L, Vendrell L, et al. Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: a case-control study. Drug Saf. 2008;31:159–168.
   Google Scholar
• Dall M, Schaffalitzky de Muckadell OB, Lassen AT, et al. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. Clin Gastroenterol Hepatol. 2009;7:1314–1321.
   Google Scholar
• Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13–37.
   Google Scholar
• Claire RJ, Servis ME, Cram DL. Potential interaction between warfarin sodium and fluoxetine. Am J Psychiatry. 1991;148:1604.
   Google Scholar
• Woolfrey S, Gammack N, Dewar M, et al. Fluoxetine-warfarin interaction. Br Med J. 1993;307:241.
   Google Scholar
• Dent LA, Orrock MW. Warfarin-fluoxetine and diazepam-fluoxetine interaction. Pharmacotherapy. 1997;17:170–172.
   Google Scholar
• Yap KB, Low ST. Interaction of fluvoxamine with warfarin in an elderly woman. Singapore Med J. 1999;40:480–482.
   Google Scholar
• Limke KK, Shelton AR, Elliott ES. Fluvoxamine interaction with warfarin. Ann Pharmacother. 2002;36:1890–1892.
   Google Scholar
• Bannister SJ, Houser VP, Hulse JD, et al. Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand. 1989;80:102–106.
   Google Scholar
• Apseloff G, Wilner KD, Gerber N, et al. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet. 1997;32:37–42.
   Google Scholar
• Priskorn M, Sidhu JS, Larsen F, et al. Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol. 1997;44:199–202.
   Google Scholar
• Kurdyak PA, Juurlink DN, Kopp A, et al. Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol. 2005;25:561–564.
   Google Scholar
• Schalekamp T, Klungel OH, Souverein PC, et al. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med. 2008;168:180–185.
   Google Scholar
• Wallerstedt SM, Gleerup H, Sundström A, et al. Risk of clinically relevant bleeding in warfarin-treated patients—influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;5:412–416.
   Google Scholar
• Hauta-Aho M, Tirkkonen T, Vahlberg T, et al. The effect of drug interactions on bleeding risk associated with warfarin therapy in hospitalized patients. Ann Med. 2009;41:619–628.
   Google Scholar
• Schelleman H, Brensinger CM, Bilker WB, et al. Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study. PLoS One. 2011;6:e21447.
   Google Scholar
• Teichert M, Visser LE, Uitterlinden AG, et al. Selective serotonin re-uptake inhibiting antidepressants and the risk of overanticoagulation during acenocoumarol maintenance treatment. Br J Clin Pharmacol. 2011;72:798–805.
   Google Scholar
• Quinn GR, Singer DE, Chang Y, et al. Effect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin. Am J Cardiol. 2014;114:583–586.
   Google Scholar
• Dong YH, Bykov K, Choudhry NK, et al. Clinical outcomes of concomitant use of warfarin and selective serotonin reuptake inhibitors. A multidatabase observational cohort study. J Clin Psychopharmacol. 2017;37:200–209.
   Google Scholar
• Glueck CJ, Khalil Q, Winiarska M, et al. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA. 2006;295:1517–1518.
   Google Scholar
• Monastero R, Camarda R, Camarda C. Potential drug–drug interaction between duloxetine and acenocoumarol in a patient with alzheimer’s disease. Clin Ther. 2007;29:2706–2709.
   Google Scholar
• Chappell J, He J, Knadler MP, et al. Effects of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady state in healthy subjects. J Clin Pharmacol. 2009;49:1456–1466.
   Google Scholar
• De Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65:795–803.
   Google Scholar
• Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. Br J Clin Pharmacol. 2008;66:76–81.
   Google Scholar
• Cheng YL, Hu HY, Lin XH, et al. Use of SSRI, but not SNRI, increased upper and lower gastrointestinal bleeding. A nationwide population-based cohort study in Taiwan. Medicine (Baltimore). 2015;94:e2022.
   Google Scholar
• Nishimura H, Kawakami M. A case with the increased PT-INR after the addition of mirtazapine to warfarin therapy. Seishin Shinkeigaku Zasshi. 2015;117:820–825.
   Google Scholar
• Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry. 2002;47:375–377.
   Google Scholar
• Salazar DE, Dockens RC, Milbrath RL, et al. Pharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects. J Clin Pharmacol. 1995;35:730–738.
   Google Scholar
• Hardy JL, Sirois A. Reduction of prothrombin and partial thromboplastin times with trazodone. CMAJ. 1986;135:1372.
   Google Scholar
• Small NL, Giamonna KA. Interaction between warfarin and trazodone. Ann Pharmacother. 2000;34:734–736.
   Google Scholar
• Jalili M, Dehpour AR. Extremely prolonged INR associated with warfarin in combination with both trazodone and omega-3 fatty acids. Arch Med Res. 2007;38:901–904.
   Google Scholar
• Bavle AD, Phatak AS. Bupropion-warfarin combination: a serious complication. Indian J Psychol Med. 2013;35:311–313.
   Google Scholar
• Chen G, Zhang W, Serenko M. Lack of effect of multiple doses of vortioxetine on the pharmacokinetics and pharmacodynamics of aspirin and warfarin. J Clin Pharmacol. 2015;55:671–679.
   Google Scholar
• Kasper S, Caraci F, Forti B, et al. Efficacy and tolerability of hypericum extract for the treatment of mild to moderate depression. Eur Neuropsychopharmacol. 2010;20:747–765.
   Google Scholar
• Ge B, Zhang Z, Zuo Z. Updates on the clinical evidenced herb-warfarin interactions. Evid Based Complement Alternat Med. 2014;2014:957362.
   Google Scholar
• Russo E, Scicchitano F, Whalley BJ, et al. Hypericum perforatum: pharmacokinetic, mechanismof action, tolerability, and clinical drug-drug interactions. Phytother Res. 2014;28:643–655.
   Google Scholar
• Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol. 2004;57:592–599.
   Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   Google Scholar
• Quinn GR, Hellkamp AS, Hankey GJ, et al. Selective serotonin reuptake inhibitors and bleeding risk in anticoagulated patients with atrial fibrillation: an analysis from the ROCKET AF trial. J Am Heart Assoc. 2018;7:e008755.
   Google Scholar
• Forbes HL, Polasek TM. Potential drug–drug interactions with direct oral anticoagulants in elderly hospitalized patients. Ther Adv Drug Saf. 2017;8:319–328.
   Google Scholar
• de Leon J. Evidence-based medicine versus personalized medicine: are they enemies? J Clin Psychopharmacol. 2012;32:153–164.
   Google Scholar
• Vandenbroucke JP. Observational research, randomised trials, and two views of medical science. PLoS Med. 2008;5:e67.
   Google Scholar
• Vandenbroucke JP. In defense of case reports and case series. Ann Intern Med. 2001;134:330–334.
   Google Scholar
• Rogers T, de Leon J, Atcher D. Possible interaction between warfarin and quetiapine. J Clin Psychopharmacol. 1999;19:382–383.
   Google Scholar
• Spina E, de Leon J. Potentially clinically relevant pharmacodynamic interactions between antiepileptic drugs and psychotropic drugs: an update. Curr Pharm Des. 2017;23:5625–5638.
   Google Scholar
• Trifirò G, Spina E. Age-related changes in pharmacodynamics: focus on drugs acting on central nervous and cardiovascular systems. Curr Drug Metab. 2011;12:611–620.
   Google Scholar
• Douros A, Dell’Aniello S, Dehghan G, et al. Degree of serotonin reuptake inhibition of antidepressants and ischemic risk: A cohort study. Neurology. 2019;93:e1010-e1020. .
   Google Scholar
• de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: pharmacological issues and further understanding. Rev Psiquiatr Salud Ment. 2015;8:167–188.
   Google Scholar
• Lund M, Petersen TS, Dalhoff KP. Clinical implications of p-glycoprotein modulation in drug-drug interactions. Drugs. 2017;77:859–883.
   Google Scholar